Overview
Discounted cash flow
Income / accounting-based
Multiples & assets
Scenario
Toolbox
Weighted blend
$580.32
+85.72% vs spot
Strong Buy
Spot price
$312.48
Mkt cap $8.45B
subtle cardAnalyst PT consensus
$321.67
+2.94% vs spot
subtle cardMethods covered
4 / 4
3 in blend
subtle cardFootball field
BIO · fair-value range by method
Method comparison
BIO · fair value by valuation framework
| Method | Category | Fair value | Range | vs spot | Weight | Driver | Conf. |
|---|---|---|---|---|---|---|---|
| Justified P/E | multiple | $0.00 | $0.00 – $0.00 | -100.00% | — | Fair P/E 0.0 (payout 0%, kₑ 9.2%, g -5.0%) | low |
| P/E · sector | multiple | $613.14 | $539.56 – $686.72 | +96.22% | 92.3% | EPS 27.87 × peer P/E 22.0 | med |
| Graham revised | intrinsic | $233.71 | $198.65 – $268.76 | -25.21% | 3.8% | EPS×(8.5+2g)·4.4/Y | low |
| Lynch P/E=g | intrinsic | $139.35 | $118.45 – $160.25 | -55.41% | 3.8% | PE = g (-5.0) | low |
Cost-of-capital build-up
CAPM cost of equity, after-tax cost of debt, WACC. Risk-free as of 2026-05-12.
| Risk-free rate (US 10y Treasury)rf | 4.46% |
| Equity beta (1.06)β | × 1.06 |
| Equity risk premiumERP | 4.46% |
| Cost of equity (CAPM)kₑ | 9.19% |
| Pre-tax cost of debtkd | 3.20% |
| Effective tax ratet | 24.1% |
| After-tax cost of debt | 2.43% |
| Equity weight$7.5B | 83.0% |
| Debt weight$1.5B | 17.0% |
| WACC | 8.04% |
Growth assumptions
Blended forward growth used as DCF default; terminal pegged to long-run nominal GDP.
| Analyst forward revenue growthFMP | -0.28% |
| Analyst forward EPS growthFMP | -67.56% |
| Historical 5y revenue CAGRFY | -3.04% |
| Historical 5y EPS CAGRFY | -80.21% |
| Sustainable g (ROE × retention)Δ | 10.20% |
| Blended near-term growth (g₀) | -5.00% |
| Terminal growth (gₗ) | 2.00% |
Sources
- FMP /analyst-estimates— 8 rows(as of 2023-12-31)
- Treasury rates · 10y— 4.46% rf(as of 2026-05-12)
- market_risk_premium · DB— 4.46% ERP(as of 2026-05-13)
- Sector multiple defaults— Healthcare (live sector PE unavailable)
- FMP /price-target-consensus— mean $321.67
This page is generated by a quantitative valuation engine for research purposes only and does not constitute investment advice. Methodology follows standard CFA / Damodaran frameworks; assumptions are driven by analyst consensus from Financial Modeling Prep and reported financial statements.